文献速递浆细胞疾病

长基因间非编码RNA对多发性骨髓瘤生存具有独立影响

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.
PubMed 文献 · Leukemia · 2018-03-29

研究对308例初诊统一治疗患者及16例正常浆细胞行RNA测序,并利用CoMMpass研究532例初诊患者数据,发现869个差异表达长基因间非编码RNA(lincRNA),14个与无进展生存(PFS)相关并构建风险评分;高风险组PFS与总生存(OS)均显著劣于低风险组,且在细胞遗传学/FISH、ISS及微小残留病(MRD)分层内仍可进一步区分结局。

要点

  • 多发性骨髓瘤(MM)与正常浆细胞间存在869个差异表达lincRNA。
  • 14个lincRNA构成风险评分,高风险组PFS 17个月 vs 低风险组未达到(NR)。
  • 验证队列高风险组PFS 27 vs 42个月(HR 2.06),4年OS 62% vs 86%(HR 2.76)。

核心结论

  • lincRNA对多发性骨髓瘤结局具有独立影响,并为评估其分子和生物学影响提供了依据。

研究设计与样本

  • 对308例初诊且统一治疗患者的骨髓瘤细胞及16例正常浆细胞行RNA测序,并利用CoMMpass研究532例初诊患者的RNA测序数据分析lincRNA。

主要发现

  • 多发性骨髓瘤与正常浆细胞相比,观察到869个差异表达lincRNA。
  • 识别出14个与PFS相关的lincRNA并计算风险评分以对患者分层。
  • 高风险组 vs 低风险组中位PFS为17个月 vs 未达到(NR),中位OS为30个月 vs NR(两者p < 0.0001)。
  • 独立验证数据集中高风险组 vs 低风险组PFS为27 vs 42个月(HR 2.06 [1.44-2.96];p < 0.0005),4年OS为62% vs 86%(HR 2.76 [1.51-5.05];p < 0.0005)。
  • lincRNA特征可在基于细胞遗传学/FISH、ISS及MRD阴性或阳性的标准风险分类所确定的低风险和高风险类别内,进一步识别结局显著不同的患者。

关键数值与推荐

  • 14个lincRNA与PFS相关并用于计算风险评分。
  • 高风险组 vs 低风险组中位PFS 17个月 vs NR,中位OS 30个月 vs NR(p < 0.0001)。
  • 验证集高风险组 vs 低风险组PFS 27 vs 42个月(HR 2.06 [1.44-2.96];p < 0.0005)。
  • 验证集高风险组 vs 低风险组4年OS 62% vs 86%(HR 2.76 [1.51-5.05];p < 0.0005)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although long intergenic non-coding RNAs (lincRNA) role in various cancers is described, their significance in Multiple Myeloma (MM) remains poorly defined. Here we have studied the lincRNA profile and their clinical impact in MM. We performed RNA-seq on MM cells from 308 newly diagnosed and uniformly treated patients, 16 normal plasma cells and utilized RNA-seq data from 532 newly diagnosed patients from CoMMpass study to analyze for lincRNAs. We observed 869 differentially expressed lincRNAs in MM compared to normal plasma cells. We identified 14 lincRNAs associated with PFS and calculated a risk score to stratify patients. The median PFS between high vs low-risk groups was 17 months vs not-reached (NR); and OS 30 months vs NR, respectively (p < 0.0001 for both). In the independent validation dataset between high and low-risk groups, PFS was 27 vs 42 months (HR 2.06 [1.44-2.96]; p < 0.0005); and 4-year OS 62% vs 86% (HR 2.76 [1.51-5.05]; p < 0.0005) confirming significant clinical relevance of lincRNA in MM. Importantly, lincRNA signature was able to further identify patients with significant differential outcomes within each low and high-risk categories identified using standard risk categorization including cytogenetic/FISH, ISS, and MRD negative or positive. Our results suggest that lincRNAs have an independent effect on MM outcome and provide a rationale to evaluate its molecular and biological impact.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Samur MK, Minvielle S, Gulla A, et al. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018. PMID: 29749396. doi:10.1038/s41375-018-0116-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。